Table 2:
Clinical characteristics at diagnosis and treatment of women with stages I-III breast cancer in the SABCHO cohort by HIV status
| HIV negative | HIV positive | Total | P-value | |
|---|---|---|---|---|
| HIV status (row %) | 1868 (78.9%) | 499 (21.1%) | 2367 (100.0%) | |
| Tumour stage | ||||
| T0 | 4 (0.2) | 1 (0.2) | 5 (0.2) | 0.401* |
| T1 | 201 (10.8) | 41 (8.2) | 242 (10.2) | |
| T2 | 820 (43.9) | 212 (42.5) | 1032 (43.6) | |
| T3 | 300 (16.1) | 88 (17.6) | 388 (16.4) | |
| T4 | 543 (29.1) | 157 (31.5) | 700 (29.6) | |
| Nodal stage | ||||
| 0 | 649 (34.7) | 132 (26.5) | 781 (33.0) | 0.003 |
| 1 | 772 (41.3) | 226 (45.3) | 998 (42.2) | |
| 2 | 362 (19.4) | 109 (21.8) | 471 (19.9) | |
| 3 | 85 (4.6) | 32 (6.4) | 117 (4.9) | |
| Stage | ||||
| Stage I | 142 (7.6) | 23 (4.6) | 165 (7.0) | 0.017 |
| Stage II | 819 (43.8) | 206 (41.3) | 1025 (43.3) | |
| Stage III | 907 (48.6) | 270 (54.1) | 1177 (49.7) | |
| Histological diagnosis | ||||
| Invasive ductal | 1782 (95.4) | 483 (96.8) | 2265 (95.7) | 0.172 |
| Other histological type | 86 (4.6) | 16 (3.2) | 102 (4.3) | |
| Grade | ||||
| Grade 1 | 123 (7.7) | 30 (7.0) | 153 (7.5) | 0.883 |
| Grade 2 | 880 (55.0) | 239 (55.7) | 1119 (55.1) | |
| Grade 3 | 598 (37.3) | 160 (36.3) | 758 (37.3) | |
| Breast cancer subtype | ||||
| a ER+ or PR+/HER2− | 1163 (62.3) | 271 (54.3) | 1434 (60.6) | 0.003 |
| ER+/PR+/HER2+ | 299 (16.0) | 111 (22.2) | 410 (17.3) | |
| ER−/PR−/HER2+ | 117 (6.3) | 31 (6.2) | 148 (6.3) | |
| ER−/PR−/HER2− | 289 (15.5) | 86 (17.2) | 375 (15.8) | |
| KI67 | ||||
| <20 | 581 (32.3) | 130 (27.3) | 711 (31.2) | 0.036 |
| ≥20 | 1220 (67.7) | 347 (72.7) | 1567 (68.8) | |
| Surgical treatment | ||||
| No | 434 (23.2) | 137 (27.5) | 571 (24.1) | 0.050 |
| Yes | 1434 (76.8) | 362 (72.5) | 1796 (75.9) | |
| Chemotherapy treatment | ||||
| No | 522 (27.9) | 88 (17.6) | 610 (25.8) | <0.001 |
| Yes | 1346 (72.1) | 411 (82.4) | 1757 (74.2) | |
| Radiation therapy | ||||
| No | 893 (47.8) | 248 (49.7) | 1141 (48.2) | 0.452 |
| Yes | 975 (52.2) | 251 (50.3) | 1226 (51.8) | |
| Treatment received | ||||
| Surgery, no chemotherapy | 303 (16.2) | 40 (8.1) | 343 (14.5) | <0.001 |
| Surgery + chemotherapy | 1131 (60.5) | 322 (65.5) | 1453 (61.4) | |
| Chemotherapy, no surgery | 215 (11.5) | 89 (17.8) | 304 (12.8) | |
| No surgery or chemotherapy | 219 (11.7) | 48 (9.6) | 267 (11.3) | |
| Endocrine therapy (ER+/PR+ patients only, N=1844) | ||||
| No | 252 (17.2) | 81 (21.2) | 333 (18.1) | 0.073 |
| Yes | 1210 (82.8) | 301 (78.8) | 1511 (81.9) | |
| b Median follow-up time in months (IQR) | 29.0 (19.0–42.0) | 26.0 (17.0–38.0) | 29.0 (19.0–41.0) | <0.001 |
Abbreviations:
a
ER/PR (Oestrogen receptor/Progesterone receptor), HER2 (Human Epidermal Growth Factor Receptor 2),
b
IQR (Interquartile range). Missing data: Grade (n=337), Ki67 (n=89).
*
Fisher’s exact test